S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Recruiting · NCT05101070 · Registry updated 2026-03-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors | Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-03-18 | NCT05101070 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| Shionogi | 14 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Angeles Clinic and Research Center | Los Angeles | United States | 1 |
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Henry Ford Health Center | Detroit | United States | 1 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| National Cancer Center Hospital | Chuo Ku | Japan | 5 |
| National Cancer Center Hospital East | Kashiwa | Japan | 15 |
| The University of Osaka Hospital | Suita | Japan | 5 |
| University of Florida Health | Gainesville | United States | 13 |